Skip to main content

Table 5 Frequency of symptoms among patients using a DuoBaby nebulizer equipped (cases, n = 43) or not equipped (controls; n = 46) with a nasal aspirator stratified for the use of controller therapy (Inhaled Corticosteroid, ICS)

From: The impact of nasal aspiration with an automatic device on upper and lower respiratory symptoms in wheezing children: a pilot case-control study

  Cases Controls   
control therapy no control therapy control therapy no control therapy   
n = 6 n = 37 n = 10 n = 36 pb pc
Mediana IQR Mediana IQR Mediana IQR Mediana IQR
Nasal symptoms in the last 24 h 40.4 (30.8–74.9) 23.2 (13.3–41.2) 54.2 (49.3–57.9) 39.7 (24.9–58.5) 0.020 0.011
Bronchial symptoms in the last 24 h 40.6 (39.6–56.1) 20.8 (12.5–32.3) 34.6 (27.8–50.4) 29.7 (15–50.1) 0.035 0.031
  1. aMedian (IQR) of the percentages of days with symptoms calculated at individual level (see method for definition)
  2. bp-value for cases vs controls from linear regression adjusted for control therapy
  3. cMann Whitney U test was used to compare quantitative not normally distributed variables between cases vs controls groups (eliminating subjects with control therapy)
  4. No statistical differences in subjects with control therapy between cases vs controls